Skip to main content

Table 1 Baseline characteristics, treatment, and response of individual patients

From: Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia

Pt

(no.)

Age/sex

(year)

Prior therapies

(no.)

BM blasts

(%, by morphology)

BM blasts (%, by flow cytometry)

EMDs

CD7+ in blasts

(%)

CAR T-cell source/Dose (105/kg)

Grade ≥ 3

CRS/onset

(mos)

Grade ≥ 3

GVHD/onset

(mos)

Grade ≥ 3

Infection/onset (mos)

Response at day 30

Follow-up time (mos)/remission status/live status

E001

12/M

3

< 5

1.35

No

99.98

Prior-SCT/5

No

No

No

CR

9.0/Loss follow-up

E002

4/M

3

< 5

1.54

No

98.80

Prior-SCT/5

No

No

Yes/5.5

CR

5.5/Death of AE

E003

6/F

3

9.00

18.61

No

100.00

Prior-SCT/5

Yes/< 1

No

Yes/11–13.3

CR

28.8/Remission

E004

6/M

4

< 5

0.19

No

99.95

Prior-SCT/10

No

Yes/8.2

Yes/12.3

CR

12.5/Death of AE

E005

10/M

2

18.50

11.22

Throat/Ileocecal/Inguen

99.10

New/10

No

No

No

CR

28.0/Remission

E006

7/M

2

80.00

41.36

No

86.42

New/10

No

No

No

NR

0.5/Loss follow-up

E007

18/M

4

80.00

59.70

No

100.00

Prior-SCT/5

No

No

No

CR

8.8/Relapse

E008

23/M

4

< 5

0

Left neck

95.00#

Prior-SCT/10

Yes/< 1

No

No

PR

27.1/Remission

E009

19/M

4

< 5

3.86

Kidney

97.22

Prior-SCT/10

No

No

No

CR

20.8/Relapse

E010

11/F

4

< 5

1.60

No

81.18

Prior-SCT/10

No

No

Yes/5.4–6.8

CR

6.8/Death of AE

E011

10/M

2

< 5

0.90

No

100.00

New/10

No

No

No

CR

26.4//Relapse

E012

11/M

2

56.50

39.29

No

100.00

New/10

No

No

No

CR

17.0/Relapse

E013

17/M

4

84.00

87.99

CNS + Testicle

100.00

Prior-SCT/10

No

No

No

Resp*

1.8/Loss follow-up

E014

2/F

2

< 5

6.17

No

93.80

New/10

No

No

No

CR

14.9/Relapse

E015

18/M

3

6.00

5.77

CNS, Optical nerves

90.60

New/10

No

No

No

CR

24.7/Remission

E016

17/M

2

< 5

1.17

Mediastinum/Lymphonode

100.00

Prior-SCT/10

No

No

Yes/8.7

CR

8.7/Death of AE

E017

43/F

2

71.50

53.35

Breast mass

100.00

New/10

No

No

No

CR

1.7/Death of AE

E018

33/M

4

89.00

16.84

No

100.00

Prior-SCT/10

No

No

No

CR

24.2/Remission

E019

5/F

2

< 5

72.40

CNS

100.00

New/10

No

No

No

CR

24.1/Remission

E020

10/M

3

< 5

0

CNS

100.00

Prior-SCT/10

No

No

No

CR

18.3/Relapse

  1. Bold indicates patient who received new donor-derived CAR T cells at 1 × 106 (± 30%)/kg, italics indicates patient who received prior-SCT donor-derived CAR T cells at 1 × 106 (± 30%)/kg, and bolditalics indicates patient who received prior-SCT donor-derived CAR T cells at 5 × 105 (± 30%)/kg
  2. AE—adverse event; Pt—patient; no.—number; F—female; M—male; BM—bone marrow; EMDs—extramedullary diseases; CNS—central nervous system; IHC—immunohistochemistry; CR—complete remission; NR—non-response; CRS—cytokine release syndrome; GVHD—graft-versus-host disease; mos—months; SCT—stem cell transplantation
  3. *This patient achieved objective response (MRD– in BM and CSF, and reduction in EMDs) until out of trial
  4. #Determined by immunohistochemistry